Management of Medication-Related Cardiometabolic Risk in Patients with Severe Mental Illness

Current Cardiovascular Risk Reports

Volumn 7, Issue 4, 2013, Pages 283-287

  Lang, Donna J ^a   Barr, Alasdair M ^b   Procyshyn, Ric M ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b British Columbia Mental Health and Addictions Research Institute   (Canada)

Author keywords

Antipsychotics; Cardiometabolic disorder; Exercise; Mental illness

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; CHLORPROMAZINE; CLOZAPINE; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE; ZIPRASIDONE;

CARDIOMETABOLIC RISK; CLINICAL TRIAL (TOPIC); DIABETIC KETOACIDOSIS; DRUG INDUCED DISEASE; DYSLIPIDEMIA; EXERCISE; GLUCOSE INTOLERANCE; HEART ARRHYTHMIA; HUMAN; LOW DRUG DOSE; MENTAL DISEASE; META ANALYSIS (TOPIC); MOTOR ACTIVITY; MULTICENTER STUDY (TOPIC); ORTHOSTATIC HYPOTENSION; REVIEW; SEDATION; SEXUAL DYSFUNCTION; SIDE EFFECT; SUDDEN CARDIAC DEATH; SYSTEMATIC REVIEW (TOPIC); TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT GAIN;

EID: 84879911055     PISSN: 19329520     EISSN: 19329563     Source Type: Journal    
DOI: 10.1007/s12170-013-0321-1     Document Type: Review

References (47)

1. Hofer A, Rettenbacher MA, Widschwendter CG, Kemmler G, Hummer M, Fleischhacker WW. Correlates of subjective and functional outcomes in outpatient clinic attendees with schizophrenia and schizoaffective disorder. Eur Arch Psychiat & Clin Neurosci. 2006;256: 246-55.
2. Hennekens CH, Hennekens AR, Hollar B, Casey DE. Schizophrenia and increased risk of cardiovascular disease. Amer Heart J. 2005;150: 1115-21.
3. Kilbourne AM, Brar JS, Drayer RA, Xu X, Post EP. Cardiovascular disease and metabolic risk factors in male patients with schizophrenia, schizoaffective disorder, and bipolar disorder. Psychosomatics. 2007;48: 412-7.
4. Association. CP: therapeutic choices. Ottawa, CPA. 2011.
5. Bensenor IM, Brunoni AR, Pilan LA, Goulart AC, Busatto GF, Lotufo PA, et al. Cardiovascular disease in severe mental illness. Gen Hosp Psychiat. 2012;34: 268-75.
6. Verma SK, Subramaniam M, Liew A, Poon LY. Metabolic risk factors in drug-naive patients with first-episode psychosis. J Clin Psychiat. 2009;70: 997-1000.
7. Hasnain M, Victor W, Vieweg VR, Mezuk B. Mortality in schizophrenia. Neuropsychopharm. 2011;25: 846-7.
8. Newcomer JW. Antipsychotic medications: metabolic and cardiovascular risk. J Clin Psychiat. 2007;68 Suppl 4: 8-13.
9. Fagiolini A, Goracci A. The effects of undertreated chronic medical illnesses in patients with severe mental disorders. J Clin. 2009;70 Suppl 3: 22-9.
10. Goeree R, Farahati F, Burke N, Blackhouse G, O'Reilly D, Pyne J, et al. The economic burden of schizophrenia in Canada in 2004. Curr Med Res Opin. 2005;21: 2017-28.
11. Procyshyn RM, Honer WG, Wu TK, Ko RW, McIsaac SA, Young AH, et al. Persistent antipsychotic polypharmacy and excessive dosing in the community psychiatric treatment setting: a review of medication profiles in 435 Canadian outpatients. J Clin Psychiat. 2004;71: 566-73.
12. Kopala LC. Spontaneous and drug-induced movement disorders in schizophrenia. Acta Psychiatr Scand Suppl. 1996;389: 12-7.
13. Meunch J, Hamer AM. Adverse effects of antipsychotic medications. Am Fam Phys. 2010;81: 617-22.
14. Boyda HN, Tse L, Procyshyn RM, Honer WG, Barr AM. Preclinical models of antipsychotic drug-induced metabolic side-effects. Trends Pharmacol Sci. 2010;31: 484-97.
15. Leung JY, Barr AM, Procyshyn RM, Honer WG, Pang CC. Cardiovascular side effects of antipsychotic drugs: the role of the autonomic nervous system. Pharmacol Ther. 2012;135: 113-22.
16. Nyguyen D, Brakoulias V, Boyce P. An evaluation of monitoring practices in patients on second generation antipsychotics. Australas Psychiat. 2009;17: 295-9.
17. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care. 2004;27: 596-601.
18. Allison DB, Mentore JL, Heo M, Chandler LP, Cappelleri JC, Infante MC, et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry. 1999;156: 1686-96.
19. Taylor DM, McAskill R. Atypical antipsychotics and weight gain-a systematic review. Acta Psychiatr Scand. 2000;101: 416-32.
20. Tandon R, Halbreich U. The second-generation 'atypical' antipsychotics: similar improved efficacy but different neuroendocrine side effects. Psychoneuroendocrinology. 2003;28 Suppl 1: 1-7.
21. Ghaeli P, Dufresne RL. Elevated serum triglycerides on clozapine resolve with risperidone. Pharmacotherapy. 1995;15: 382-3.
22. Henderson DC, Cagliero E, Gray C, Nasrallah RA, Hayden DL, Schoenfeld DA, et al. Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: a five-year naturalistic study. Am J Psychiatry. 2000;157: 975-81.
23. Lund BC, Perry PJ, Brooks JM, Arndt S. Clozapine use in patients with schizophrenia and the risk of diabetes, hyperlipidemia, and hypertension: a claims-based approach. Arch Gen Psychiatry. 2001;58: 1172-6.
24. de Leon J, Susce MT, Johnson M, Hardin M, Pointer L, Ruano G, et al. A clinical study of the association of antipsychotics with hyperlipidemia. Schizophr Res. 2007;92: 95-102.
25. AHA: Metabolic syndrome: new guidance for prevention and treatment. AHA & NHLBI Scientific Statement, 2005.
26. McEvoy JP, Meyer JM, Goff DC, Nasrallah HA, Davis SM, Sullivan L, et al. Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophr Res. 2005;80: 19-32.
27. Newcomer JW, Haupt DW, Fucetola R, Melson AK, Schweiger JA, Cooper BP, et al. Abnormalities in glucose regulation during antipsychotic treatment of schizophrenia. Arch Gen Psychiatry. 2002;59: 337-45.
28. Henderson DC, Cagliero E, Copeland PM, Borba CP, Evins E, Hayden D, et al. Glucose metabolism in patients with schizophrenia treated with atypical antipsychotic agents: a frequently sampled intravenous glucose tolerance test and minimal model analysis. Arch Gen Psychiatry. 2005;62: 19-28.
29. Newcomer JW. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs. 2005;19 Suppl 1: 1-93.
30. Sacher J, Mossaheb N, Spindelegger C, Klein N, Geiss-Granadia T, Sauermann R, et al. Effects of olanzapine and ziprasidone on glucose tolerance in healthy volunteers. Neuropsychopharmacology. 2008;33: 1633-41.
31. Mitchell AJ, Delaffon V, Vancampfort D, Correll CU, De Hert M. Guideline concordant monitoring of metabolic risk in people treated wth antipsychotic medication: systematic review and meta-analysis of screening practices. Psychol Med. 2012;42: 125-47.
32. Raedler TJ. Cardiovascular aspects of antipsychotics. Curr Opin Psychiatry. 2010;23: 574-81.
33. De Hert M, Vancampfort D, Correll CU, Mercken V, Peuskens J, Sweers K, et al. Guidelines for screening and monitoring of cardiometabolic risk in schizophrenia: systematic evaluation. Brit J Psychiatry. 2011;199: 99-105.
34. Phillips AA, Warburton DE, Flynn SW, Fredikson D, Lang DJ. Physiological evidence of increased cardiovascular disease risk in schizophrenia-spectrum disorders: a pilot study using aortic pulse wave velocity and arterial compliance. Submitted. 2013.
35. Beebe LH, Smith KD, Roman MW, Burk RC, McIntyre K, Dessieux OL, et al. A pilot study describing phyiscal activity in persons with schizophrenia spectrum disorders (SSDS) after an exercise program. Issues Ment Health Nurs. 2013;34: 214-9.
36. Knochel C, Oertel-Knochel V, O'Dwyer L, Prvulovic D, Alves G, Kollman B, et al. Cognitive and behavioural effects of physical exercise in psychiatric patients. Prog Neurobiol. 2012;92: 46-68.
37. Blair SN, Brodney S. Effects of physical inactivity and obesity on morbidity and mortality: evidence and research issues. Med Sci Sports Exerc. 1999;31 Suppl 1: S646-57.
38. •• Bernard P, Ninot G. Benefits of exercise for people with schizophrenia: a systematic review. Encephale. 2012;38: 280-7. This recent review clearly tabulated our current evidence for the feasibility and/or efficacy of exercise interventions for both psychiatric and physical remediation.
39. Alsuwaidan MT, Kucyi A, Law CWY, McIntyre RS. Exercise and bipolar disorder: a review of neurobiological mediators. Neuro Molec Med. 2009;11: 328-36.
40. Babyak M, Blumenthal JA, Herman S, Khatri P, Doraiswamy M, Moore K, et al. Exercise treatment for major depression: maintenance of therapeutic benefit at 10 months. Psychsom Med. 2000;62: 633-8.
41. Beebe LH, Tian L, Morris N, Goodwin A, Allen SS, Kuldau J. Effects of exercise on mental and physical health parameters of persons with schizophrenia. Issues Ment Health Nurs. 2005;26: 661-76.
42. Carter T, Callaghan P, Khalil E, Morres I. The effectiveness of a preferred intensity exercise programme on the mental health outcomes of young people with depression: a sequential mixed methods evaluation. BMC Publ Health. 2012;12: 187.
43. • Lang DJ, Gigas K, Humphries BG, Honer WG, Smith GN, Thornton AE, et al. Effects of exercise on symptom severity and hippocampal volumes in treatment-resistant chronic schizophrenia: preliminary results. Proceedings of the International Congress of Schizophrenia Research, Orlando, Florida, Schizophrenia Bulletin. 2013;S340. Our new recent data demonstrate the feasibility and effectiveness of a managed exercise program in the most severely mentally ill patients to remediate mood deficits and improve physical fitness in the presence of high-dose atypical antipsychotic treatment.
44. Otte A, Hassler J, Brogowski J, Bowen JC, Mayhew JL. Relationship between body mass index and predicted % fat in college men and women. Mo J Health Physical Edn Rec Dance. 2000;10: 23-9.
45. Tavazzi L, Dubach P, Opasich C, Meyers J, Perk J, Meyer K, et al. Working group report: recommendations for exercise testing in chronic heart failure patients. Eur Heart J. 2001;22: 37-45.
46. Strassnig MT, Newcomer JW, Harvey PD. Exercise improves physical capacity in obese patients with schizophrenia: pilot study. Schiz Res. 2012;141: 284-5.
47. Scheewe TW, Takken T, Kahn RS, Cahn W, Backx FJ. Effects of exercise therapy on cardiorespiratory fitness in patients with schizophrenia. Med Sci Sports Exerc. 2012;44: 1834-42.